Pharmaceuticals North America

North America Cell and Gene Therapy CDMO Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

North America Cell and Gene Therapy CDMO Market Industry Trends and Forecast to 2034: Segmented by (Service, Product, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

North America · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $4.05 Bn Placeholder estimate
Estimate 2025 $4.81 Bn 55.7% of the global market
Projected 2034 $22.85 Bn 374.9% Adds $18.04 Bn over 9 forecast years
CAGR 2025–2034 18.9% Faster than 86% of 180 Pharmaceuticals markets here
Key players 6 +1
  • North America is 55.68% of the global market.
  • Among regions, the largest is North America (this report) at $4.81 Bn.
  • Fastest growing: Africa at 21.5% a year.
  • North America ranks 1st of 6 by size among regions.

Market size projection

North America

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$18.04 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Cell and Gene Therapy CDMO Market market size by year, North America
YearMarket sizeChange that yearSince 2025
2024 (estimate) $4.05 Bn — —
2025 (base) $4.81 Bn +$764.7 Mn —
2026 (forecast) $5.72 Bn +$909.2 Mn +18.9%
2027 (forecast) $6.80 Bn +$1.08 Bn +41.4%
2028 (forecast) $8.09 Bn +$1.29 Bn +68.1%
2029 (forecast) $9.61 Bn +$1.53 Bn +99.9%
2030 (forecast) $11.43 Bn +$1.82 Bn +137.6%
2031 (forecast) $13.59 Bn +$2.16 Bn +182.5%
2032 (forecast) $16.16 Bn +$2.57 Bn +235.9%
2033 (forecast) $19.22 Bn +$3.05 Bn +299.4%
2034 (forecast) $22.85 Bn +$3.63 Bn +374.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

North America Cell and Gene Therapy CDMO Market Analysis at a glance
Market size, 2025$4.81 Bn placeholder estimate
Forecast, 2034$22.85 Bn placeholder estimate
Growth (CAGR), 2025–203418.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsService, product and end user (see all)
Key playersLonza Ltd, Catalent, Charles River Laboratories, WuXi AppTec, AGC Biologics and 1 more (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The North America Cell and Gene Therapy CDMO Market Analysis Executive Summary

Cell and gene therapy CDMOs are contract companies that develop and manufacture cell and gene therapies for biotech and pharma firms.

Key segments of the cell and Gene Therapy CDMO market include service (Process Development, Clinical Manufacturing and Commercial Manufacturing) and product (Viral Vectors, Cell Therapies and Plasmid DNA).

Bar chart: North America Cell and Gene Therapy CDMO market size, 2024–2034, placeholder estimates. $4.05 Bn in 2024, $4.81 Bn in 2025 and $22.85 Bn in 2034, 18.9% CAGR.
North America Cell and Gene Therapy CDMO market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

North America Cell and Gene Therapy CDMO Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the cell and Gene Therapy CDMO market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the cell and Gene Therapy CDMO market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the cell and Gene Therapy CDMO market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for Cell and Gene Therapy CDMO Market in North America

The cell and Gene Therapy CDMO market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Cell and Gene Therapy CDMO Market in North America

Cell and Gene Therapy CDMO in North America: rules and payment

In the countries we cover here, medicines are approved by Health Canada (Canada)⁠[1] and FDA (US)⁠[2]. How care is paid for in these countries: provincial health insurance (Canada)⁠[3] and Medicare and Medicaid (US)⁠[4].

[1] Health Canada. Checked 14 Nov 2026.

[2] US Food and Drug Administration. Checked 14 Nov 2026.

[3] Health Canada. Checked 14 Nov 2026.

[4] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for cell and Gene Therapy CDMO. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in North America.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Cell and Gene Therapy CDMO right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Cell and Gene Therapy CDMO in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Cell and Gene Therapy CDMO market in North America?
Placeholder estimate: about $4.81 Bn in 2025, rising to about $22.85 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Cell and Gene Therapy CDMO market in North America growing?
Placeholder estimate: about 18.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Cell and Gene Therapy CDMO market report cover?
The report splits the market by service (Process Development, Clinical Manufacturing, Commercial Manufacturing, Testing), product (Viral Vectors, Cell Therapies, Plasmid DNA) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Cell and Gene Therapy CDMO market?
Key players include Lonza Ltd, Catalent, Charles River Laboratories, WuXi AppTec, AGC Biologics and Samsung Biologics.
What is driving the Cell and Gene Therapy CDMO market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the cell and Gene Therapy CDMO market.
Back to Catalogue

Related Pharmaceuticals reports in North America

See all

Related on cell and gene therapy and drug development and manufacturing

See the topic